The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma
Open accessAbstract
The relationship between overexpression of glypican (GPC)‐3 that is specific for hepatocellular carcinoma (HCC) and the prognosis has not yet been clarified. We attempted to determine the expression profile of GPC3 in association with the clinicopathological factors by immunohistochemical analysis in HCC patients and investigated the potential prognostic value of GPC3 by comparing the survival rate between the GPC3‐positive and GPC3‐negative HCC patients. Primary HCC tissue samples (n = 107) obtained from patients who had undergone hepatectomy between 2000 and 2001 were analyzed. GPC3 expression was less frequently observed in well‐differentiated HCC than in moderately and poorly differentiated HCC, the difference in the frequency being statistically significant. GPC3‐positive HCC patients had a significantly lower 5‐year survival rate than the GPC3‐negative HCC patients (54.5 vs 87.7%, P = 0.031). Among 80 of the 107 (74.6%) patients with initial treatment who underwent hepatectomy, none of GPC3‐negative HCC patients (n = 16, 20.0%) died during the follow‐up period. No deaths were noted in the GPC3‐negative HCC patients among the 71 (88.7%) patients with moderately and poorly differentiated HCC. Multivariate analysis identified GPC3 expression (P = 0.034) as an independent prognostic factor for the overall survival. We showed that GPC3 expression is correlated with a poor prognosis in HCC patients. (Cancer Sci 2009)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Stigliano, I. D., Puricelli, L., Filmus, J., Sogayar, M. C., Joffé, E. B. D. K., & Peters, M. G. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0009-2 · Cited by 82
RetractedGlypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Portolani, N., Coniglio, A., Ghidoni, S., Giovanelli, M., Benetti, A., Tiberio, G. A. M., & Giulini, S. M. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000197706.21803.a1 · Cited by 857
Poon, R. T.-P., Fan, S.-T., Ng, I. O.-L., Lo, C.-M., Liu, C.-L., & Wong, J. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<500::aid-cncr4>3.0.co;2-o · Cited by 729
Filmus, J., Capurro, M., & Rast, J. (2008) · Genome Biology · doi:10.1186/gb-2008-9-5-224 · Cited by 556
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
Capurro, M. I., Xiang, Y.-Y., Lobe, C., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4244 · Cited by 469
Glypican-3 as a Serum Marker for Hepatocellular Carcinoma
Capurro, M., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.372.65.1 · Cited by 432
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
Nakatsura, T., Yoshitake, Y., Senju, S., Monji, M., Komori, H., Motomura, Y., Hosaka, S., Beppu, T., Ishiko, T., Kamohara, H., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00908-2 · Cited by 430
Self-citationDi Tommaso, L., Franchi, G., Park, Y. N., Fiamengo, B., Destro, A., Morenghi, E., Montorsi, M., Torzilli, G., Tommasini, M., Terracciano, L., et al. (2007) · Hepatology · doi:10.1002/hep.21531 · Cited by 427
Hepatocellular Carcinoma: The Need for Progress
Thomas, M. B., & Zhu, A. X. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.196 · Cited by 406
Cited by
Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3044 · Cited by 302
Self-citationBiomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1129483 · Cited by 178
Self-citationZhu, X., Yuan, J., Zhu, T., Li, Y., & Cheng, X. (2016) · The FEBS Journal · doi:10.1111/febs.13839 · Cited by 143
Tsuchiya, N., Yoshikawa, T., Fujinami, N., Saito, K., Mizuno, S., Sawada, Y., Endo, I., & Nakatsura, T. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1346764 · Cited by 67
Self-citation
Metadata
- Authors
- Shirakawa, H., Suzuki, H., Shimomura, M., Kojima, M., Gotohda, N., Takahashi, S., Nakagohri, T., Konishi, M., Kobayashi, N., Kinoshita, T., & Nakatsura, T.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2009-07-10
- Volume
- 100
- Issue
- 8
- Pages
- 1403-1407
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2005335309
- Cited by
- 279
- References
- 24
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1111/j.1349-7006.2009.01206.x
- The paper
- Shirakawa, H., Suzuki, H., Shimomura, M., Kojima, M., Gotohda, N., Takahashi, S., Nakagohri, T., Konishi, M., Kobayashi, N., Kinoshita, T., & Nakatsura, T. (2009). Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Science. https://doi.org/10.1111/j.1349-7006.2009.01206.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
